chenodeoxycholic acid has been researched along with pulmicort in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 14 (82.35) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Carotti, A; Colliva, C; De Franco, F; Filipponi, P; Franco, P; Gadaleta, RM; Gioiello, A; Macchiarulo, A; Moschetta, A; Mostarda, S; Passeri, D; Pellicciari, R; Roda, A | 1 |
| Carotti, A; Ciaccioli, G; Gioiello, A; Passeri, D; Pellicciari, R; Pittol, JMR; van Mil, SWC | 1 |
| Carlsson, AH; Magnusson, KE; Münch, A; Ost, A; Söderholm, JD; Ström, M | 1 |
| Lindor, KD; Silveira, MG | 1 |
| Bowlus, CL; Cazzagon, N; Floreani, A; Franceschet, I; Gershwin, ME; Perini, L | 1 |
| Bowlus, CL; Gershwin, ME; Invernizzi, P; Lleo, A; Mousa, HS | 1 |
| Floreani, A; Mangini, C | 1 |
| Strassburg, CP | 1 |
| Anaya, JM; Gershwin, ME; Lleo, A; Marzorati, S | 1 |
| Bossen, L; Grønbæk, H; Hamberg, O; Jepsen, P; Ott, P; Ytting, H | 1 |
| Goldstein, J; Levy, C | 1 |
| Aguilera, L; Albillos, A; Martínez, J | 1 |
| Kowdley, KV; Shah, RA | 1 |
11 review(s) available for chenodeoxycholic acid and pulmicort
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.
Topics: Bile Acids and Salts; Budesonide; Chenodeoxycholic Acid; Humans; Liver Cirrhosis, Biliary; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid | 2014 |
New therapies for primary biliary cirrhosis.
Topics: Biological Factors; Budesonide; Chenodeoxycholic Acid; Clinical Trials as Topic; Fibric Acids; Humans; Liver Cirrhosis, Biliary; Treatment Outcome | 2015 |
Advances in pharmacotherapy for primary biliary cirrhosis.
Topics: Autoimmune Diseases; Bile Acids and Salts; Budesonide; Chenodeoxycholic Acid; End Stage Liver Disease; Female; Fibric Acids; Humans; Liver; Liver Cirrhosis, Biliary; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Treatment Failure; Ursodeoxycholic Acid | 2015 |
Primary biliary cholangitis: Old and novel therapy.
Topics: Budesonide; Chenodeoxycholic Acid; Disease Progression; End Stage Liver Disease; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Randomized Controlled Trials as Topic; Ursodeoxycholic Acid | 2018 |
[Modern treatment of primary biliary cholangitis].
Topics: Bezafibrate; Budesonide; Chenodeoxycholic Acid; Cohort Studies; Female; Fenofibrate; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Male; Multicenter Studies as Topic; PPAR alpha; Pregnancy; Prognosis; Quality of Life; Receptors, Cytoplasmic and Nuclear; Risk Assessment; Treatment Outcome; Ursodeoxycholic Acid | 2018 |
Primary biliary cholangitis: a comprehensive overview.
Topics: Anti-Inflammatory Agents; Autoimmune Diseases; Biopsy; Budesonide; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholangitis; Fibric Acids; Humans; Immunosuppressive Agents; Liver; Prognosis; Ursodeoxycholic Acid | 2017 |
[New name and new treatments for primary biliary cholangitits].
Topics: Anti-Inflammatory Agents; Budesonide; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholangitis; Fibric Acids; Humans; Liver Cirrhosis, Biliary; Liver Transplantation; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2018 |
Novel and emerging therapies for cholestatic liver diseases.
Topics: Bile Acids and Salts; Budesonide; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholangitis, Sclerosing; Cholestasis; Drug Therapy, Combination; Elasticity Imaging Techniques; Humans; Immunosuppressive Agents; Liver; Liver Cirrhosis, Biliary; Receptors, Cytoplasmic and Nuclear; Ursodeoxycholic Acid | 2018 |
Risk stratification and treatment of primary biliary cholangitis.
Topics: Adult; Age Factors; Alkaline Phosphatase; Biomarkers; Budesonide; Chenodeoxycholic Acid; Cholagogues and Choleretics; Cholangitis; Cholestasis; Disease Progression; Fibric Acids; Glucocorticoids; Humans; Liver Cirrhosis; Liver Transplantation; Middle Aged; Risk Assessment; Risk Factors; Sex Factors; Treatment Failure; Ursodeoxycholic Acid | 2019 |
Current and potential treatments for primary biliary cholangitis.
Topics: Benzothiazoles; Bezafibrate; Bile Acids and Salts; Budesonide; Case-Control Studies; Chenodeoxycholic Acid; Cholagogues and Choleretics; Clinical Trials as Topic; Cyclosporine; Disease Progression; Glucocorticoids; Homeostasis; Humans; Immunologic Factors; Immunosuppressive Agents; Isoxazoles; Liver Cirrhosis, Biliary; Liver Transplantation; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Rituximab; Treatment Outcome; United States; United States Food and Drug Administration; Ursodeoxycholic Acid | 2020 |
6 other study(ies) available for chenodeoxycholic acid and pulmicort
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Discovery of 3α,7α,11β-Trihydroxy-6α-ethyl-5β-cholan-24-oic Acid (TC-100), a Novel Bile Acid as Potent and Highly Selective FXR Agonist for Enterohepatic Disorders.
Topics: | 2016 |
Dissecting the allosteric FXR modulation: a chemical biology approach using guggulsterone as a chemical tool.
Topics: | 2019 |
Low levels of bile acids increase bacterial uptake in colonic biopsies from patients with collagenous colitis in remission.
Topics: Adult; Aged; Aged, 80 and over; Bile Acids and Salts; Biological Transport; Biopsy; Budesonide; Case-Control Studies; Chenodeoxycholic Acid; Colitis, Collagenous; Deoxycholic Acid; Escherichia coli K12; Female; Gastrointestinal Agents; Humans; In Vitro Techniques; Male; Microscopy, Confocal; Middle Aged | 2011 |